ClinicalTrials.gg
Not yet recruitingNCT07863089Updated Oct 7, 2026

RECONNECT - Treatments for Complex PTSD

An interventional study of Prolonged Exposure and EMDR in Complex Post-Traumatic Stress Disorder (CPTSD), sponsored by University of Copenhagen. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by University of Copenhagen · Not applicable, Interventional, and Treatment

How we know

Updated Oct 7, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
225
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Complex PTSD (CPTSD) is a new diagnosis for which no established gold-standard treatment(s) yet exists. In this trial, three psychotherapies, Prolonged Exposure (PE), Eye Movement Desensitization and Reprocessing (EMDR), and Enhanced Skills Training in Affective and Interpersonal Regulation (ESTAIR), are compared in a multisite trial. Methods: The study is a single-blinded, pragmatic, non-inferiority, multi-center randomized controlled trial (RCT) comparing ESTAIR, EMDR vs PE for CPTSD, each delivered as 18 weekly individual sessions. In total, 315 patients will be recruited from three outpatient clinics in the Capital Region of Denmark and randomized to one of the three intervention arms. The primary outcome is patient-rated CPTSD symptoms assessed with the International Trauma Questionnaire (ITQ); secondary outcomes include clinician-rated CPTSD symptoms assessed with the International Trauma interview (ITI), as well as dissociation, quality of life, attachment, interpersonal problems, and emotion regulation. Assessments are conducted before and after therapy (18 weekly sessions) treatment and at 6-month follow-up. Weekly patient- and clinician-rated outcomes are collected at every treatment session. Outcome assessors, blind to treatment allocation, will perform the observer-based symptom ratings, while fidelity assessors will monitor manual adherence.

Read the detailed description

Complex post-traumatic stress disorder (CPTSD) was introduced as a distinct diagnosis in the 11th revision of the International Classification of Diseases (ICD-11). CPTSD includes the core symptoms of post-traumatic stress disorder (PTSD)-re-experiencing, avoidance, and a persistent sense of current threat-as well as disturbances in self-organization (DSO). DSO symptoms comprise affective dysregulation, negative self-concept, and difficulties in relationships. CPTSD is frequently associated with prolonged or repeated trauma and may involve substantial functional impairment, dissociation, interpersonal difficulties, self-harm, and an increased risk of suicide.

Although CPTSD is associated with considerable clinical burden, evidence regarding its optimal treatment remains limited. No single psychological treatment has been established as the preferred evidence-based intervention for all patients with CPTSD. The heterogeneity of CPTSD also suggests that treatment response may vary according to patients' clinical characteristics. Research is therefore needed both to compare potentially effective treatments and to identify factors that may inform future treatment selection.

Interventions

Prolonged Exposure (PE) is an established trauma-focused psychological treatment for PTSD and is recommended in international clinical guidelines. However, evidence regarding its effectiveness specifically for CPTSD remains limited.

Eye Movement Desensitization and Reprocessing (EMDR) is also recommended for PTSD and has shown promising results among patients with complex trauma presentations, including dissociative symptoms and trauma related to sexual abuse. Preliminary studies indicate that EMDR may also be effective for CPTSD.

Enhanced Skills Training in Affective and Interpersonal Regulation (ESTAIR) was developed specifically for CPTSD. It is a modular treatment comprising four components that address PTSD symptoms, emotion regulation, negative self-concept, and interpersonal difficulties. The modular structure allows the clinician and patient to determine the order and emphasis of the treatment components according to the patient's needs.

### Objectives

The primary objective is to compare the effectiveness of individual PE, EMDR, and ESTAIR among adult psychiatric outpatients with a primary diagnosis of CPTSD.

The primary outcome is CPTSD symptom severity. Secondary outcomes include quality of life, dissociation, interpersonal difficulties, and emotion-regulation difficulties. The study will also explore whether baseline patient characteristics predict treatment outcomes or moderate the comparative effects of the three interventions.

Hypothesis

The primary hypothesis is that ESTAIR and EMDR will each be non-inferior to PE, which represents treatment as usual, in reducing CPTSD symptoms. CPTSD symptoms are measured using the International Trauma Questionnaire (ITQ) from baseline to post-treatment and at the 6-month follow-up. The predefined non-inferiority margin is 6 points on the ITQ.

Study Design

RECONNECT is an investigator-initiated, multicenter, randomized, assessor-blinded, three-arm, non-inferiority clinical trial. A total of 315 adults aged 18-65 years with a primary diagnosis of CPTSD will be recruited from three outpatient clinics within the Danish Mental Health Services.

Participants will be randomly allocated in equal proportions to one of three individual psychological treatments:

  • Prolonged Exposure (PE)
  • Eye Movement Desensitization and Reprocessing (EMDR)
  • Enhanced Skills Training in Affective and Interpersonal Regulation (ESTAIR)

Each intervention consists of 18 weekly individual sessions lasting approximately 60 minutes. Outcomes will be assessed at baseline, during treatment, immediately after treatment, and at follow-up. Outcome assessors will be blinded to treatment allocation.

02

Conditions studied

  • Complex Post-Traumatic Stress Disorder (CPTSD)

Keywords

  • Psychotherapy
  • Prolonged Exposure
  • EMDR
  • ESTAIR
03

In context

Stress Disorders, Post-Traumatic

2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

This study's planned enrollment of 225 is above the median of 69 across 2,203 interventional studies indexed under Stress Disorders, Post-Traumatic.

Browse Stress Disorders, Post-Traumatic studies →

Lead sponsor

University of Copenhagen is the lead sponsor of 466 studies on the registry; 64 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

a) CPTSD as the primary diagnosis (ICD-11 code 6B41) measured with International Trauma Questionnaire ((ITQ) Cloitre et al., 2021); b) age 18-65; c) no alcohol or substance abuse; d) no concurrent psychotherapy; e) medication free or stable on psychotropic medication for at least five weeks; f) fluency in Danish; and g) written .

Exclusion criteria

Exclusion Criteria:

  1. concurrent psychotherapy
  2. changed dosage on psychotropic medication
  3. not fluent in Danish
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
225 participants (estimated)

Study arms

  • Active comparator
    Prolonged Exposure

    PE is a manualized, trauma-focused exposure therapy aimed at facilitating emotional processing of traumatic memories. In this study, PE is delivered over 18 sessions and includes three core components: (1) psychoeducation about trauma and PTSD, including a rationale for exposure-based treatment and the role of avoidance and maladaptive beliefs in maintaining symptoms; (2) in vivo exposure, involving repeated and graded confrontation with objectively safe but trauma-related situations, typically conducted as homework; and (3) imaginal exposure, in which patients repeatedly recount the traumatic memory aloud in session, followed by therapeutic processing and between-session listening to audio recordings. Through repeated exposure, PE seeks to modify maladaptive beliefs and reduce symptoms by enabling patients to integrate corrective information and process trauma-related distress (McLean \& Foa, 2011).

    Behavioral: Prolonged Exposure

  • Experimental
    Eye Movement Desensitization and Reprocessing

    EMDR is an eight-phase, trauma-focused psychotherapy designed to facilitate the processing of distressing memories. In this study, EMDR is delivered over 18 sessions. Core elements include focusing on emotionally salient aspects of traumatic memories while engaging in bilateral stimulation (e.g., eye movements, sounds, or tapping), with brief feedback provided between stimulation sets to monitor processing. This process is repeated until the memory no longer elicits distress. The eight phases encompass history-taking, preparation, assessment, reprocessing, closure, and re-evaluation. EMDR follows a three-pronged approach targeting past experiences, present triggers, and future templates, aiming to promote adaptive resolution reflected in changes in emotions, cognitions, somatic responses, and behavior (F. Shapiro, 1995; F. Shapiro \& Maxfield, 2002). In our trial we use the Standard EMDR Protocol (E. Shapiro \& Laub, 2014) with Developmental sensitive interventions.

    Behavioral: EMDR

  • Experimental
    Enhanced Skills Training in Affective and Interpersonal Regulation

    ESTAIR is a modular, manualized treatment for CPTSD, delivered in 18 sessions in this study. It includes an initial case formulation followed by four modules: (1) affect regulation, targeting identification and modulation of emotions, distress tolerance, and acceptance; (2) disturbances in relationships, focusing on maladaptive schemas, assertiveness, and interpersonal flexibility; (3) negative self-concept, including self-narrative, addressing dissociation, self-compassion, mindfulness, and cognitive restructuring; and (4) PTSD, involving trauma memory processing through verbal narration and cognitive reappraisal, targeting core PTSD symptoms.

    Behavioral: ESTAIR

Interventions

  • BehavioralProlonged Exposure

    All treatments are delivered as 18 weekly, individual, 1-hour sessions by trauma clinicians (psychologists and psychiatrists), who will be trained and certified in all three interventions at the beginning of the project. To ensure treatment quality and adherence to the manuals, clinicians will receive bi-weekly video-based group supervision in the first year and then titrated to monthly in the second year and onwards. All three arms follow the same outpatient-clinic guidelines: 1) treatment must be offered within 30 days of referral; 2) treatment duration is 18 weeks; 3) treatment is discontinued if a patient misses four sessions. Each arm will be trained and supervised by a specialist in that treatment: the EMDR-arm by EMDR specialist Sophie Hallin Iuel-Brockdorff; the ESTAIR arm by Prof. Marylene Cloitre, who developed the intervention; and the PE-arm by PE-specialist Sandra Capaldi, a member of the late Prof. Edna Foa's team. Although PE serves as TAU, we have matched the clinical t

  • BehavioralEMDR

    All treatments are delivered as 18 weekly, individual, 1-hour sessions by trauma clinicians (psychologists and psychiatrists), who will be trained and certified in all three interventions at the beginning of the project. To ensure treatment quality and adherence to the manuals, clinicians will receive bi-weekly video-based group supervision in the first year and then titrated to monthly in the second year and onwards. All three arms follow the same outpatient-clinic guidelines: 1) treatment must be offered within 30 days of referral; 2) treatment duration is 18 weeks; 3) treatment is discontinued if a patient misses four sessions. Each arm will be trained and supervised by a specialist in that treatment: the EMDR-arm by EMDR specialist Sophie Hallin Iuel-Brockdorff; the ESTAIR arm by Prof. Marylene Cloitre, who developed the intervention; and the PE-arm by PE-specialist Sandra Capaldi, a member of the late Prof. Edna Foa's team. Although PE serves as TAU, we have matched the clinical t

  • BehavioralESTAIR

    All treatments are delivered as 18 weekly, individual, 1-hour sessions by trauma clinicians (psychologists and psychiatrists), who will be trained and certified in all three interventions at the beginning of the project. To ensure treatment quality and adherence to the manuals, clinicians will receive bi-weekly video-based group supervision in the first year and then titrated to monthly in the second year and onwards. All three arms follow the same outpatient-clinic guidelines: 1) treatment must be offered within 30 days of referral; 2) treatment duration is 18 weeks; 3) treatment is discontinued if a patient misses four sessions. Each arm will be trained and supervised by a specialist in that treatment: the EMDR-arm by EMDR specialist Sophie Hallin Iuel-Brockdorff; the ESTAIR arm by Prof. Marylene Cloitre, who developed the intervention; and the PE-arm by PE-specialist Sandra Capaldi, a member of the late Prof. Edna Foa's team. Although PE serves as TAU, we have matched the clinical t

06

What researchers measure

Primary outcomes

  1. International Trauma Questionnaire

    Self-report measuring CPTSD symptoms, with 18-items assessing for ICD-11 PTSD and complex PTSD (CPTSD). Respondents are asked to identify "the experience that troubles you the most" along with how long ago it occurred. Then they are asked to respond to symptom and functioning questions. Items are rated on a 5-point scale ranging from 0 ("not at all") to 4 ("extremely"). The scale ranges from 0 to 24 for PTSD symptoms and 0 to 24 for DSO symptoms, with higher scores reflecting greater symptom severity.

    Time frame: From enrollment to 28 weeks post intervention

07

Study locations

No study locations are listed for this record.

08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Data cannot be shared publicly because our dataset involves subjects who did not explicitly consent to the publication of their pseudonymized data with is required to comply with the Danish Data Protection Act. Therefore, publishing the dataset does not align with the ethical standards of data management and regulations upheld at the University of Copenhagen. Data are available from the Data Management and Information Security department at the Department of Psychology, University of Copenhagen (contact via legal@samf.ku.dk) for researchers who meet the criteria for access to confidential data.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2027; primary completion for Jul 2029, 23 months later.

Of 1,066 non-industry interventional studies with no phase under Stress Disorders, Post-Traumatic, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 23 months is below that.

Counting every sponsor, half of 1,094 studies reached it within 35 months; a quarter within 17 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2026
First posted
Oct 7, 2026
StartEst.
Jul 31, 2027
Primary completionEst.
Jul 1, 2029
CompletionEst.
Dec 31, 2029
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07863089
Responsible party
Sponsor
First posted
Oct 7, 2026
Start date
Jul 31, 2027 (estimated)
Primary completion
Jul 1, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Oct 7, 2026

Study contacts

Sara Kerstine Kaya Nielsen, Assistant Professor, PhD
Contact
sara.nielsen@psy.ku.dk
0045 35324542

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion